

REFERENCES

REFERENCES

- Abe T. (2002):** Progress in the field of hematology in the last 100 years: Cytogenetics Nippon Naika Gakkai Zasshi. Jul 10; 91(7):1994-7. Japanese.
- Abeloff, and Martin et al., (2004):** Clinical Oncology, 3rd. edition, St. Louis, Mo.: Elsevier Churchill Livingstone, p. 2834.
- Acilan C, Potter DM, Saunders WS. (2007):** DNA repair pathways involved in anaphase bridge formation. Genes Chromosomes Cancer. 46(6): 522-31.
- Alton A. K., Fechtel K.: Terry A. L.; Meikle S. B.: Muskavitch M. A. T. (1988):** Cytogenetics definition and morphogenetic analysis of Delta, a gene affecting neurogenesis in Drosophila melanogaster Genetics (Genetics) ISSN 00166731 CODEN GENTAE, vol, 118, no2, pp.235-245.
- American Cancer Society (2004):** what is acute lymphocytic leukemia, detailed guide: leukemia-Adult Acute. Cancer reference information. May.
- Andrieu V, Radford-Weiss I, Troussard X, et al (1996):** Molecular detection of t(8;21)/AML1-ETO in AML M1/M2: correlation with cytogenetics, morphology and immunophenotype. Br J Haematol; 92: 855-865.
- Appelbaum FR (2002):** "Keynote address: hematopoietic cell transplantation beyond first remission". *Leukemia* 16 (2): 157-9.
- Appelbaum FR, Baer MR, Carabasi MH, et al (2000):** "NCCN Practice Guidelines for Acute Myelogenous Leukemia". *Oncology (Williston Park, N.Y.)* 14 (11A): 53-61.
- Appelbaum FR., Rosenblum D., Arceci RJ., et al., (2007):** End points to establish the efficacy of new agents in the treatment of acute leukemia. *Blood*; 109:1810.

- Aquino VM, Schneider NR, Sandler ES. (2001):** Secondary myelodysplasia with monosomy 7 arising after treatment for acute lymphoblastic leukemia in childhood. *J Pediatr Hematol Oncol.*; 23(1): 48-50.
- Babu KA, Verma RS. (1985):** Structural and functional aspects of nucleolar organizer regions (NORs) of human chromosomes. *Int Rev Cytol.*; 94: 151-76.
- Bacher U, Kern W, Schoch C, et al. (2006):** Evaluation of complete disease remission in acute myeloid leukemia: a prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia. *Cancer* 106 (4): 839-47, 2006
- Baer M.R., Stewart C.C., Lawrence D. et al. (1998):** Acute myeloid leukemia with 11q23 translocations: myelomonocytic immunophenotype by multiparameter flow cytometry. *Leukemia* 12 , pp. 317-325.
- Bagg A (2001):** Commentary: minimal residual disease: how low do we go? *Mol Diagn*, 6:155-160.
- Barbui T, Falanga A (2001):** Disseminated intravascular coagulation in acute leukemia. *Semin Thromb Hemost* 27 (6): 593-604.
- Bear MR. (1999):** Cytogenetics. In: Lee, G.R., Foerester, G., Luken, J.N., Greer, J.P. and Rodgers, G.M. (eds): *Wintrobe's Clinical Hematology*. Williams Wilkins, Baltimore, USA. Vol. I, 10th edition. , P.98.
- Beghini A., Ripamonti CB., Cairoli R., et al., (2004):** KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. *Haematologica* 89 (8): 920-5.
- Bene MC., Bernier M., Casasnovas RO. et al., (2001):** Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients. *British Journal of Haematology* 113 .pp. 737-745.

References

- Berkowicz M, Rosner E, Rechavi G, et al, (1991):** Atypical chronic myelomonocytic leukemia with eosinophilia and translocation (5;12). A new association. *Cancer Genet Cytogenet.*; 51(2): 277-8.
- Bernard OA, Busson-LeConiat M, Ballerini P. et al, (2001):** A new recurrent and specific cryptic translocation, t (5; 14) (q35; q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia. *Leukemia* 15, pp. 1495–1504.
- Bhatia S., Neglia JP. (1995):** "Epidemiology of childhood acute myelogenous leukemia". *J. Pediatr. Hematol. Oncol.* 17 (2): 94-100.
- Bielas JH, Loeb KR, Rubin BP, True LD, Loeb LA. (2006):** Human cancers express a mutator phenotype. *Proc Natl Acad Sci USA.*; 28; 103(48): 18238-42.
- Bishop J (1997):** "The treatment of adult acute myeloid leukemia". *Semin Oncol* 24 (1): 57–69.
- Bishop JF, Matthews JP, Young GA, et al (1996):** "A randomized study of high-dose cytarabine in induction in acute myeloid leukemia". *Blood* 87 (5): 1710-7.
- Bloomfield CD, Lawrence D, Byrd JC, et al.(1998):** Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. *Cancer Res* 58 (18): 4173-9.
- Boomer T, Varella-Garcia M, McGavran L, et al, (2001):** Detection of E2A translocations in leukemia via fluorescence in situ hybridization. *Leukemia* ; 15(1): 95-102.
- Brunning RD, Matutes E, Flandrin G, et al. (2001):** Acute myeloid leukaemia with recurrent genetic abnormalities. In: Jaffe ES, Harris NL, Stein H, et al., eds.: *Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues*. Lyon, France: IARC Press. World Health Organization Classification of Tumours, 3, pp 81-7.

- Burke DT, Carle GF, Olson MV (1987):** Cloning of large segments of exogenous DNA into yeast by means of artificial chromosome vectors. *Science*; 236(4803):806-12.
- Burnett AK, Grimwade D, Solomon E. (1999):** Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. *Blood*; 93:4131-4143.
- Burnette ALK, Wheatley K, Langabeer S, et al (1997):** Outcome of acute myeloid leukemias affecting core binding factor subunits: The UK MRC experience. *Blood* 90: 390a.
- Bustin M. Goldblatt D. Sperling R. (1976):** Chromatin structure visualization by immunoelectron microscopy. *Cell*. Feb; 7(2):297-304.
- Byrd JC, Mrózek K, Dodge RK, et al. (2002):** Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). *Blood* 100 (13): 4325-36.
- Byrd JC, Mrózek K, Dodge RK, et al.(2002):** Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). *Blood* 100 (13): 4325-36.
- Caligiuri MA, Strout MP, Gilliland DG (1997):** Molecular biology of acute myeloid leukemia. *Semin Oncol* 24 (1): 32-44.
- Casasnovas RO., Slimane FK., Garand R. et al., (2003):** Immunological classification of acute myeloblastic leukemias: relevance to patient outcome. *Leukemia* 17, pp. 515-527.
- Casillas JN., Woods WG., and Hunger SP., et al., (2003):** Prognostic implications of t (10; 11) translocations in childhood acute myelogenous leukemia: a report from the Children's Cancer Group. *J Pediatr Hematol Oncol* 25 (8): 594-600.

References

- Cassileth PA, Harrington DP, Hines JD, et al (1988):** "Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia". *J. Clin. Oncol.* 6 (4): 583-7.
- Cheson BD., Bennett JM., Kopecky KJ., et al., (2003):** Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. *J Clin Oncol*; 21:4642.
- Chong S.S., Boehm C.D., Higgs D.R. and Cutting G.R. (2000):** Single-tube multiplex-PCR screen for common deletional determinants of alpha-thalassemia. *Blood*, 95(1): 360-362.
- Choppa P.C., Gomez J., Vall H.G. and Owens M. (2003):** A novel method for the detection, quantitation, and breakpoint cluster region determination of t(15;17) fusion transcripts using a one-step real-time multiplex PCR. *Am J Clin Pathol.*, 119(1): 137-144.
- Cigudosa JC, Otero MD, Calasanz MJ, et al. (2003):** De novo erythroleukemia chromosome features include multiple rearrangements, with special involvement of chromosomes 11 and 19. *Genes Chromosomes Cancer* 36 (4): 406-12.
- Clouston HJ. Herbert M. Fenwick J. et al, (2002):** Cytogenetic analysis of human blastocysts. *Prenat Diagn.* Dec; 22(12):1143-52,
- Cytogenetics information site, basic cytogenetics. August 2004.**
- Dalcin P, Atkins L, Ford C, et al, (2001):** Amplification of AML1 in childhood acute lymphoblastic leukemia. *Genes Chromosomes Cancer*; 30(4): 407-9.
- Demidov VV. Wachowiaki J (2002):** "A happy marriage: advancing DNA polymerases with DNA topoisomerases supplements". *Trends Biotechnol.* 20: 491.

References

- Devita VT, Hellman S, Rosenberg SA, (2002):** Acute leukemia, In: principles and practice of oncology, 6th edition, Lippincott Williams and Wilkins; Chapter. 5, p: 2256-2342.
- Dobyns WB, Curry CJ, Hoyme HE, et al, (1991):** Clinical and molecular diagnosis of Miller-Dieker syndrome. Am J Hum Genet.; 48(3): 584-94.
- Dollinger, Malin (1994):** Everyone's Guide to Cancer Therapy. Toronto: Somerville House Books. Ltd.
- Du Manoir S, Speicher MR, Joos S, et al, (1993):** Detection of complete and partial chromosome gains and losses by comparative genomic in situ hybridization. Hum Genet; 90(6): 590-610.
- Duchayne E., Fenneteau O., and Pages MP., et al., (2003):** Acute megakaryoblastic leukaemia: a national clinical and biological study of 53 adult and childhood cases by the Groupe Français d'Hématologie Cellulaire (GFHC). Leuk Lymphoma 44 (1): 49-58.
- Duesberg P, Fabarius A, Hehlmann R. (2004):** Aneuploidy, the primary cause of the multipotential genomic instability of neoplastic and preneoplastic cells. IUBMB Life. 56(2): 65-81.
- Dupont M., Goldsborough A., Levayer T., et al (2002):** Multiplex Fluorescent RT-PCR to quantify leukemic fusion transcripts. Biotechniques, 33: 158-164.
- Dutcher JP, Schiffer CA, Wiernik PH (1987):** Hyperleukocytosis in adult acute nonlymphocytic leukemia: Impact on remission rate and duration, and survival. Journal of Clinical Oncology 5(9): 1364-1372.
- Elihu H. (1995):** Detection of minimal residual cell in ALL by the FISH method: potential for predicting relapse. Blood; 11: 495.
- Elnifro E.M., Ashi A.M., Cooper R.J. and Klapper P.E. (2000):** Multiplex PCR: optimization and application in diagnostic virology. Clin. Microbiol. Rev., 13(4): 559-70.

References

- Erickson P, Gao J, Chang KS. (1992):** Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. *Blood*.80:1825-1831.
- Estey E (2002):** "Treatment of acute myelogenous leukemia". *Oncology (Williston Park)* 16 (3): 343–52, 355–6; discussion 357, 362, 365–6.
- Faderl L, Kantarjian H, Talpaz M. and Estrov Z. (1998):** Clinical significance of cytogenetic abnormalities in adult ALL. *Blood*, 91:3995-4005.
- Fauth C, Speicher MR. (2001):** Classifying by colors: FISH-based genome analysis. *Cytogenet Cell Genet*; 93(1-2): 1-10.
- Fenaux P, Chastang C, Chevret S, et al. (1999):** A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. *Blood* 94 (4): 1192-200.
- Ferrando A.A. and Look A.T. (2000):** Clinical implications of recurring chromosomal and associated molecular abnormalities in acute lymphoblastic leukemia. *Semin Hematol* 37 (2000), pp. 381–395
- Ferrando AA, Armstrong SA, Neuberg DS, et al, (2003):** Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. *Blood*; 102(1): 262-8.
- Fineli P, Antonacci R, Marzella R, et al, (1996):** Structural organization of multiple alphoid subsets coexisting on human chromosomes 1, 4, 5, 7, 9, 15, 18, and 19. *Genomics* ; 38(3): 325-30.
- Forterre P. (2006):** "DNA topoisomerase V: a new fold of mysterious origin". *Trends Biotechnol.* 24:245-247.
- Fotios A, Asmakopoulos TLH, Elizabeth PN and Michael AS. (1996):** Detection of chromosome 20q deletion in bone marrow metaphases but no peripheral blood granulocytes in patients with MPD or MDS. *Blood*; 87: 1561-66.

- Friedman JM, Dill FJ, Hayden MR and McGillivray BC. (1992):** Genetics. Egyptian Ed. Mass Publishing Co., Hong Kong and London; p: 25-30.
- Gamerding U, Teigler-Schlegel A, Pils S, Bruch J, et al, (2003):** Cryptic chromosomal aberrations leading to an AML1/ETO rearrangement are frequently caused by small insertions. *Genes Chromosomes Cancer*. 36(3): 261-72.
- Gardiner K. (1995).** Human genome organization. *Curr Opin Genet Dev*. 5(3): 315-22.
- Ge Y., Stout ML., Tatman DA., et al., (2005):** GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. *J Natl Cancer Inst* 97 (3): 226-31.
- Gibson U.E., Heid C.A. and Williams P.M. (1996):** A novel method for real time quantitative RT-PCR. *Genome Res.*, 6(10):995-1001.
- Giugliano E, Rege-Cambrin G, Scaravaglio P, et al. (2002):** Two new translocations involving the 11q23 region map outside the MLL locus in myeloid leukemias. *Haematologica* 87 (10): 1014-20.
- Goad K.E and Gralnick H.R, (1996).** Coagulation disorders in cancer, *Hematol Oncol Clin North Am* 10, pp. 457-484.
- Graham JM Jr. Hoehn H. Lin MS. Smith DW. (1981):** Diploid-triploid mixoploidy: clinical and cytogenetic aspects. *Pediatrics*. Jul: 68(1):23-8.
- Greef GE., van Putten WL., Boogaerts, M., et al., (2005):** Criteria for defining a complete remission in acute myeloid leukemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies. *Br J Haematol*; 128:184.
- Greenlee RT., Hill-Harmon MB, Murray T., Thun M. (2001):** CA Cancer J Clin 51 (1): 15-36.

- Greer JP., Baer MR. and Kinney MC. (2004):** Acute myeloid leukemia in adults. In: Wintrob's Clinical Hematology, 11th edition, P.2097. By: Greer JP, Rodgers GM, Foerster J, Paraskevas F, Lukens JN and Glader B (eds). Lippincott Williams & Wilkins, Philadelphia.
- Greig GM, Parikh S, George J, et al, (1991):** Molecular cytogenetics of alpha satellite DNA from chromosome 12: fluorescence in situ hybridization and description of DNA and array length polymorphisms. *Cytogenet Cell Genet* ; 56(3-4): 144-8.
- Grimwade D, Howe K, Davies L, Langabeer S. (1996):** Establishing the presence of the t(15;17) in suspected APL, cytogenetic, molecular and PML immunofluorescence assessment of patients entered in the UK MRC ATRA trial. *Br J Hematol* ; 93(2): 221-29.
- Grimwade D, Walker H, Harrison G., (2001):** The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. *Blood* 98(5): 1312-20.
- Grimwade D., Walker H., Oliver F., et al (1998):** The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. *Blood* 92, 2322–2333.
- Grogan L, Kirsch IR. (2007):** Genetic Testing for Cancer Risk Assessment: A Review. *Oncologist*; 2(4): 208-222.
- Guan XY, Zhang H and Bittner M. (1996):** Chromosome arm painting probes. *Nat Genet* , 12:10.
- Gurbuxani S., Vyas P., and Crispino JD. (2004):** Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. *Blood* 103 (2): 399-406.
- Haferlach T., Kern W., Schnittger S., and Schoch C. (2005):** Modern diagnostics in acute leukemia. *Critical Reviews in Oncology/Haematology*. Volum 56, Issue 2, Pages 223-234.

- Haferlach T., Kern W., Schnittger S., Hiddemann W. and Schoch C. (2003):** The definition of complete remission in acute myeloid leukemia needs to be modernized: a study on 268 patients analyzed at 569 timepoints during follow-up by cytomorphology and interphase FISH as well as by immunophenotyping and PCR, *Blood* **102** (2003) (11), p. 876.
- Han JY, Kim KE, Kim KH, Park JI, Kim JS (2007):** Identification of PML-RARA rearrangement by RT-PCR and sequencing in an acute promyelocytic leukemia without t(15;17) on G-banding and FISH. *Leukemia Research* **31**, p239-243.
- Harris I, Jaffe ES, Diebold J, et al, (2000):** The world health organization classification of neoplasms of the haematopoietic and lymphoid tissues: report of the clinical advisory Committee Meeting-Airlie House, Virginia, *Mol Pathol*; **13**(2): 193-207.
- Harris N., Jaffe E., Diebold J., et al, (1999):** The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia. *Ann Oncol* **10** (12): 1419-32.
- Harrison C.J. (2001):** The detection and significance of chromosomal abnormalities in childhood acute lymphoblastic leukemia. *Blood Reviews* **15**, 49-59.
- Hayashi S, Toyoshima H, Tanabe N, Miyanishi K. (1996):** Daily peaks in the incidence of sudden cardiac death and fatal stroke in Niigata Prefecture. *Jpn Circ J.* ; **60**(4): 193-200.
- Hayne CC, Winer E, Williams T, Chaves F, Khorsand J, Mark HF. (2006):** Acute lymphoblastic leukemia with 4;11 translocation analyzed by a multi-model strategy of conventional cytogenetics, FISH, morphology, flow cytometry and molecular genetics, and review of the literature. *Exp Mol Pathol.* 2006. Aug; **81**(1):62-71. Epub Jun 12.

- Henegariu O, Bray-Ward P, Artan S, et al, (2001):** Small marker chromosome identification in metaphase and interphase using centromeric multiplex FISH (CM-FISH). *Lab Invest*. 81(4): 475-81.
- Hiddemann W. and Buchner T. (2001):** Current status and perspectives of therapy for acute myeloid leukemia. *Semin Hematol* 38, pp. 3–9.
- Hoffbrand AV, Petit JE and Moss PAH, (2001):** Acute leukemias. In: Essential Haematology. 4th edition chapter 12. Hoffbrand AV., Petit JE and Moss PAH (edit.), Blackwell Science Ltd. Oxford London; P: 162.
- Hoffman, Ronald et al., (2005):** Hematology: Basic Principles and Practice, 4th. ed., St. Louis, Mo.: Elsevier Churchill Livingstone, 1074–75.
- Hokland P. and Pallisgaard N.(2000):** Integration of molecular methods for detection of balanced translocations in the diagnosis and follow-up of patients with leukemia. *Semin Hematol* 37 (2000), pp. 358–367.
- Hrusak O. and Porwit-MacDonald A. (2002):** Antigen expression patterns reflecting genotype of acute leukemias. *Leukemia* 16, pp. 1233–1258.
- Huang B. Thangavelu M. Bhatt S. et al, (2002):** Prenatal diagnosis of 45, X and 45, X mosaicism: the need for thorough cytogenetic and clinical evaluation. *Prenat Diagn*. Feb; 22(2):105-10.
- Huang M, Li C, Liang H, Zhou J, Deng J, Liu W.(2006):** Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 chromosomal translocation in hematologic malignancies. *J Huazhong Univ Sci Technolog Med Sci.*; 26(6):661-3.
- Hunter T. (1997):** Oncoprotein networks. *Cell*. ; 88(3): 333-46.
- ISCN (1995):** An International System for Human Cytogenetic Nomenclature. Mitelman F. (Ed). Basel, Switzerland, p: 55.
- Iwakuma T, Lozano G (2003):** MDM2, an introduction. *Mol Cancer Res*. ; 1(14): 993-1000.

References

- Karen Seiter (2006)**, MD, Acute Myelogenous Leukemia WebMD, Inc January 24, 2006.
- Keagle MB and Gersen SL (1999)**: Basic laboratory procedures. In: Steven L. Gerson and Martha B Keagle (eds): The Principles of Clinical Cytogenetics. Human Press Inc. New Jersey. p: 71.
- Kearney L, Horsley SW. (2005)**. Molecular cytogenetics in haematological malignancy: current technology and future prospects. *Chromosoma*. 2005 Sep; 114(4) :286-94. Epub Oct 15,
- Kelly L., Clark J. and D. Gilliland D.G. (2002)**: Comprehensive genotypic analysis of leukemia: Clinical and therapeutic implications. *Curr Opin Oncol* 14 , pp. 10–18.
- Kern W, Haferlach C, Haferlach T, Schnittger S. (2008)**. Monitoring of minimal residual disease in acute myeloid leukemia. *Cancer*. 112(1): 4-16.
- Kjeldsberg CR, Johnson KE and Foucar K (2000)**: Acute myeloid leukemia. In practical diagnosis of hematologic disorder. 3rd ed. Joshua Weikersheimer publisher, p.411.
- Kohda A, Taguchi H, Okumura K. (2001)**. Preparation of extended metaphase chromosomes from human cultured cells using a topoisomeraseII Inhibitor, ICRF-193. *Biosci Biotechnol Biochem*. May; 65(5): 1248-51.
- König M, Reichel M, Marschalek R, et al (2002)**: A highly specific and sensitive fluorescence in situ hybridization assay for the detection of t(4;11)(q21;q23) and concurrent submicroscopic deletions in acute leukaemias. *Br J Haematol* 116 (4): 758-64.
- Kopnin BP (2000)**. Targets of oncogenes and tumor suppressors: key for understanding basic mechanisms of carcinogenesis. *Biochemistry (Mosc)*; 65(1): 2-27.

- Krauter J, Peter W, Pascheberg U, et al (1998):** Detection of karyotypic aberrations in acute myeloblastic leukaemia: A prospective comparison between PCR/FISH and standard cytogenetics in 140 patients with de novo AML. *Br J Haematol* 103:72-78.
- Krekulova L, Rehak Z, E.Wakil A, Harris E. and Riley L.W. (2001):** Nested restriction site-specific PCR to detect and type HCV: a rapid method to *J.Clin. Microbiol.*, 39(5):1774-1780.
- Kwaan HC, Wang J, Boggio LN (2002):** Abnormalities in hemostasis in acute promyelocytic leukemia. *Hematol Oncol* 20 (1): 33-41.
- Lacayo NJ, Meshinchi S, Kinnunen P, et al., (2004):** Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. *Blood* 104 (9): 2646-54.
- Lai LA, Paulson TG, Li X, et al, (2007):** Increasing genomic instability during premalignant neoplastic progression revealed through high resolution array-CGH. *Genes Chromosomes Cancer*. 46(6): 532-42.
- Langabeer SE, Walker H, Gale RE, et al (1997):** Frequency of CBFbeta/MYH11 fusion transcripts in patients entered into the U.K. MRC AML trials. The MRC Adult Leukaemia Working Party. *Br J Haematol* 1997; 96: 736-739.
- Langabeer SE, Walker H, Rogers JR, et al (1997):** Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials. MRC Adult Leukaemia Working Party. *Br J Haematol*; 99: 925-928.
- Leblanc T, Auvrignon A, Michel G, et al (1996):** Prognosis value of cytogenetics in 250 children with acute myeloblastic leukemia treated in the LAME 89/91 protocol. *Blood*. 88 (Suppl 1): 634a.
- Leone G, Voso MT, Sica S, et al. (2001):** Therapy related leukemias: susceptibility, prevention and treatment. *Leuk Lymphoma* 41 (3-4): 255-76.

References

- Levine AJ, Finlay CA, Hinds PW (2004).** P53 is a tumor suppressor gene. *Cell*. 2004; 116(2 Suppl): S67-9, 1p following S69.
- Levis M, Small D (2003):** FLT3: ITD Does matter in leukemia. *Leukemia* 17 (9): 1738- 52.
- Li MM. (2005).** Advanced molecular and cytogenetic technologies in birth defect diagnosis and preventin. *Beijing Da Xue Bao*. Feb 18:37(1): 14-9.
- Lichtman MA and Liesveld JK. (2001):** Acute myelogenous leukemia. In: William's Hematology, 5th edition, P.209. By: Beutler E, Collier BS, Lichtman MA, Kipps TJ and Seligsohn U (eds). McGraw-Hill, USA.
- Lichtman MA, and Liesveld JL, (2001).** Acute myelogenous leukemia. In: William's Hematology; Beutler E, Lichtman MA, Collier BS, Kipps TJ, Seligsohn U, (editors), 6th edition, New York, St Louis: McGraw-Hill; New York, USA; Ch.2, p: 1047.
- Lie SO., Abrahamsson J., Clausen N., et al., (2003):** Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials. *Br J Haematol* 122 (2): 217-25.
- Lindee MS. (2002).** Genetic disease in the 1960s: a Structural evolution. *Am J Med Genet*. Aug 30; 115(2): 75-82.
- Liu P, Tarle SA, Hajra A (1993):** Fusion between transcription factor CBF /PEBP2 and a myosin heavy chain in acute myeloid leukemia. *Science*; 261:1041-1044.
- Loeb KR, Loeb LA (2000).** Significance of multiple mutations in cancer. *Carcinogenesis*. 21(3): 379-85.
- Loeb LA, Loeb KR, Anderson JP (2003).** Multiple mutations and cancer. *Proc Natl Acad Sci U S A*. 4,100(3): 776-81.
- Look AT. (1997):** Oncogenic transcription factors in the human acute leukemias. *Science*. 278(5340): 1059-64.

- Lowenberg B, Griffin JD, Tallman MS, (2003).** Acute myeloid leukemia and acute promyelocytic leukemia. Hematology, (Am Soc Hemato Educ Program); 82-101.
- Lu YJ, Williamson D, Clark J, et al, (2001):** Comparative expressed sequence hybridization to chromosomes for tumor classification and identification of genomic regions of differential gene expression. Proc Natl Acad Sci U S A.; 98(16): 9197-202.
- Lui Q, Nozari G. and Sommr S.S. (1998):** Sinle tube PCR for rapid diagnosis of the inversion hotspot of mutation in hemophilia A. Blood, 92(4): 1458-9.
- Ma L, Li JY, Pan JL, et al, (2006):** The value of multiplex fluorescence in situ hybridization in the detection of complex karyotypic abnormalities of acute myeloid leukemia Zhonghua Xue Ye Xue Za Zhi. May, 27(5): 318-22.
- Ma Z., Morris SW., Valentine V., et al., (2001):** Fusion of two novel genes, RBM15 and MKL1, in the t (1; 22) (p13; q13) of acute megakaryoblastic leukemia. Nat Genet 28 (3): 220-1.
- Martinez-Climent J.A. (1997):** Molecular cytogenetics of childhood hematological malignancies. Leukemia 11, 1999–2021.
- Mckenzie SB (2005):** Advances in understanding the biology and genetics of acute myelocytic Leukemia. Clin Lab Sci: 18(1): 28-37.
- Mensink E., Van de Locht A., Schattenbeg A., et al, (1998):** Quantitation of MRD in Philadelphia chromosome positive chronic myeloid leukemia patients using real-time quantitative RT-PCR. Br. J. Hematol., 102 (3) L 768-774.
- Meshinchi S, Smith FO, Arceci RJ, (2003).** Prognostic factors and risk based therapy in pediatric acute myeloid leukemia. Curr Oncol Rep; 5(6): 489-497.

References

- Michalova K. (1996).** Fluorescence in situ hybridization (FISH) in cytogenetics of leukemia. *Folia Biol (Praha)*. 42(6): 311-4.
- Miller K.B. and Grodman H.M. (2001),** Leukemia. In: Lenhard R.E., Osteen R.T. and Gansler T., Editors, *Clinical Oncology*, American Cancer Society, Atlanta, GA, pp. 527-551.
- Miller KB. and Daoust PR. (2000):** Clinical manifestations of acute myeloid leukemia. In: Basic principals and practice, 3rd edition, P.999. By: Hoffman R., Benz EJ., Shattil SJ., Furie B., Cohen HJ., Silberstein LE., and McGlave P. (eds). Churchill Livingstone, Philadelphia.
- Mistry AR., Pedersen EW, Solomon E., et al., (2003):** The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. *Blood Rev* 17 (2): 71-97.
- Mitterbauer M, Laczika K, Novak M, et al (2000):** High concordance of karyotype analysis and RT-PCR for CBF beta/MYH11 in unselected patients with acute myeloid leukemia. A single center study. *Am J Clin Pathol* 113: 406-410.
- Miyamoto T, Nagafuji K, Akashi K, et al (1996):** Persistence of multipotent progenitors expressing AML1/ETO transcripts in longterm remission patients with (8;21) acute myelogenous leukemia. *Blood* 87: 4789-4796.
- Morrison LE, Legator MS and Stone JF. (1997).** Evaluation of two color ratio coding of FISH to chromosomes t(8;21). *Cytometry*. 27:14.
- Morschhauser F; Cayuela JM; Martini S; et al (2000):** Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients. *J Clin Oncol*; 18(4): p788-94.
- Mozziconacci MJ, Rosenauer A, Restouin A, et al, (2002):** Molecular cytogenetic of the acute promyelocytic leukemia-derived cell line NB4 and of four all-trans retinoic acid-resistant subclones. *Genes Chromosomes Cancer*. Nov; 35(3):261-70.

- Mrozek K, Prior TW, Fdwars C. (2001):** Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B study. *Journal of Clinical Oncology* 19(9): 2482-2492.
- Mrózek K, Heerema NA, Bloomfield CD. (2004):** Cytogenetics in acute leukemia. *Blood Rev* 18 (2): 115-36.
- Mrozek K, Heinomen K. and Bloomfield C.D. (2000):** Prognostic value of cytogenetic findings in adults with acute myeloid leukemia. *Int J Hematol* 72 , pp. 261-271.
- Muller R.F. and Young I.D. (1998):** The cellular and molecular basis of inheritance, chromosome and recombinant DNA technology. *Emery's Elements of Medical Genetics*. 10th edition. By Muller R.F., Young I.D.(eds). Churchill Livingstone, p: 11-80.
- Muller RF and Young ID. (2001).** Chromosomes. In: *Emery's elements of medical genetics*, Muller, R.F. and Young, I.D. (eds). 11th edition .Churchill living stone.; P. 29-75.
- Muller-Berndorff H, Haas PS, Kunzmann R, et al, (2006):** Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: results of a single-center analysis. *Ann Hematol*. 2006 Aug; 85(8): 502-13. Epub May 20, 2006.
- Najean Y, Rain JD. (1997):** The very long-term evolution of polycythemia vera: an analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981. *Semin Hematol*. 34(1): 6-16.
- Nasedkina T., Domer P., Zharinov V., et al, (2002):** Identification of chromosomal translocations in leukemias by hybridization with oligonucleotide microarrays. *Haematologica*, 87(4): 363-72.

References

- Nasedkina TV, Zharinov VS, Isaeva EA, et al (2003):** Clinical Screening of Gene Rearrangements in Childhood Leukemia by using a Multiplex Polymerase chain reaction-Microarray approach. Clinical cancer research. Vol. 9, 5620-5629.
- Nederlof PM, van der Flier S, Wiegant J, et al, (1990):** Multiple fluorescence in situ hybridization. Cytometry. 11(1): 126-31.
- Nicole McNeil and Thomas Ried (2000):** Novel molecular cytogenetic techniques for identifying complex chromosomal rearrangements: technology and applications in molecular medicine. Exp. Rev. Mol. Med. 14 September. 2000.
- Novelli A, Sabani M, Caiola A, et al, (1999):** Diagnosis of DiGeorge and Williams syndromes using FISH analysis of peripheral blood smears. Mol Cell Probes.13(4): 303-7.
- Olney HJ, Mitelman F, Johansson B, et al. (2002):** Unique balanced chromosome abnormalities in treatment-related myelodysplastic syndromes and acute myeloid leukemia: report from an international workshop. Genes Chromosomes Cancer 33 (4): 413-23.
- Orfao A., Chillon M.C., Bortoluci A.M. et al. (1999):** The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARalpha gene rearrangements. *Haematologica* 84 , pp. 405–412.
- Orphanos V, Santibanez-Koref M, McGown G, et al, (1994):** Physical mapping of 43 STSs to human chromosome 6. Genomics.20(2): 301-4.
- Pakakasama S, Kajanachumpol S, Kanjanapongkul S,et al (2008):** Simple multiplex RT-PCR for identifying common fusion transcripts in childhood acute leukemia. Int J Lab Hematol., 30(4):286-91.
- Pallisgaard N., Hokland P., Riishoj DC., Pedersen B. & Jorgensen P. (1998):** Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia. Blood 92, 574–588.

References

- Palmieri S, Sebastio L, Mele G, et al. (2002):** High-dose cytarabine as consolidation treatment for patients with acute myeloid leukemia with t(8;21). *Leuk Res* 26 (6): 539-43.
- Panagopoulos I, Isaksson M, Lindvall C, et al. (2003):** Genomic characterization of MOZ/CBP and CBP/MOZ chimeras in acute myeloid leukemia suggests the involvement of a damage-repair mechanism in the origin of the t(8;16)(p11;p13). *Genes Chromosomes Cancer* 36 (1): 90-8.
- Park BH, Vogelstein B (2003).** Tumor-suppressor genes. In: Kufe DW, Pollack RE, Weichselbaum RR eds. *Cancer Medicine* 6th ed. Lewiston NY: BC Decker 87-106.
- Park TS, Lee ST, Jaewoo Song J, et al (2009):** Detection of a novel CBFB/MYH11 variant fusion transcript (K-type) showing partial insertion of exon 6 of CBFB gene using two commercially available multiplex RT-PCR kits. *Cancer Genetics and Cytogenetics* 189.p 87-92
- Park TS, Lee ST, Kim JS et al (2009):** Acute promyelocytic leukemia in early pregnancy with translocation t(15;17) and variant PML/RARA fusion transcripts. *Cancer Genetics and Cytogenetics* 188; p48-51.
- Pavlov AR, Pavlova NV, Kozyavkin SA, Slesarev AI (2004):** "Thermostable Chimeric DNA Polymerases with High Resistance to Inhibitors", *DNA Amplification: Current Technologies and Applications*. Horizon Bioscience, pp. 3-20.
- Pedersen-Bjergaard J, Andersen M., Christiansen D, Nerlov C. (2002).** "Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia." *Blood* 99 (6):1909-12.
- Pfeifer J.D. and Wick M.R. (2001),** Pathologic evaluation of neoplastic disease. In: Lenhard R.E., Osteen R.T. and Gansler T., Editors, *Clinical Oncology*, American Cancer Society, Atlanta, GA, pp. 123-147.

References

- Pierce KE, Fitzgerald LM, Seibel MM, Zilberstein M. (1998):** Preimplantation genetic diagnosis of chromosome balance in embryos from a patient with a balanced reciprocal translocation. *Mol Hum Reprod.* 4(2): 167-72.
- Pierotti NA, Schichman SA, Sozzi G, Croce CM (2000):** Oncogenes. In: Bast RC, Kufe DW, Pollock RE, Weischselbaum RR, Holland JF, Frei E, eds. *Cancer Medicine*. Hamilton, Ontario: BC Decker Inc ; 56-76.
- Pinkel D, Strme T and Gray JW. (1996).** Cytogenetic analysis using quantitative, high sensitivity fluorescence hybridization. *Pro Natl Acad Sci USA.* ; 83: 2934.
- Planter I, Lai JL, Wattel E, et al, (1994):** Inv(16) may be one of the only 'favorable' factors in acute myeloid leukemia: a report on 19 cases with prolonged follow-up. *Leuk Res.*; 18(12): 885-8.
- Poirel H, Radford-Weiss I, Rack K, et al. (1995):** Detection of the chromosome 16 CBF beta-MYH11 fusion transcript in myelomonocytic leukemias. *Blood* 85 (5): 1313-22,
- Poon L.L., Wong B.W., Chan K.H., et al. (2004):** A one step quantitative RT-PCR for detection of SARS coronavirus with an internal control for PCR inhibitors. *J Clin Virol* 30, 214–217.
- Raimondi SC, Change MN, Ravindarnath Y, et al. (1999):** For the Pediatric Oncology Group. Chromosomal abnormalities in 478 children with acute myeloid leukaemia: clinical characteristics and treatment outcome in a cooperative Pediatric Oncology Group Study – POG 8821. *Blood*; 94: 3707-16.
- Ravindranath H., (2003).** Recent advances in pediatric acute lymphoblastic and myeloid leukemia. *Curr Opin Oncol*; 15(1):23-35.
- Reis LAG, Eisner MP, Kosary CL, et al, (2002).** SEER cancer statistics. National Cancer Institute; p: 1973-1999.

References

- Rennert H., Golde T., Wilson R.B., Spitalnik S.L., Deerlin V.M.D. & Leonard D.G.B. (1999):** A novel, non-nested reverse-transcriptase polymerase chain reaction (RT-PCR) test for the detecting of the t(15;17) translocation: a comparative study of RT-PCR, cytogenetics, and fluorescence in situ hybridization. *Molecular Diagnosis* 4, 195–209.
- Richard A Larson, (2008):** Remission criteria in acute myeloid leukemia and monitoring for residual disease. Bob L and Rebecca F Connor (editors). Literature review version 16.1: January 2008.
- Richard A Larson. (2007):** Treatment of acute myeloid leukemia (AML) in adults, http://patients.uptodate.com/topic.asp?file=blod_dis/2244.
- Ries LAG, Eisner MP, Kosary CL. (2002):** SEER Cancer statistics review, 1973-1999. Bethesda, MD: National cancer institute.
- Riley R.S., Massey D., Jackson-Cook C. et al (2002).,** Immunophenotypic analysis of acute lymphocytic leukemia. *Hematol Oncol Clin North Am* 16 , pp. 245–299.
- Ritterbach J, Hiddemann W, Beck JD, et al, (1998):** Detection of hyperdiploid karyotypes (>50 chromosomes) in childhood acute lymphoblastic leukemia (ALL) using fluorescence in situ hybridization (FISH). *Leukemia* ; 12(3): 427-33.
- Robert W, (2000).** Multifaceted approach to the diagnosis and classification of acute leukemia. *Clinical Chemistry*; 46: 1252-1259.
- Roberts W.M., Estrov E., Kitchingman G.R. and Zipf T.F. (1996):** The clinical significance of residual disease in childhood acute lymphoblastic leukemia as detected by PCR amplification of antigen-receptor gene sequences. *Leuk. Lymph.* 20:181-97.
- Rochelle P.A., Deleon R., Stewart M.H. and Wolfe R.L. (1997):** Comparison of primers and optimization of PCR conditions for detection of cryptosporidium parvum and giardia lamblia in water. *Appl. Environ. Microbiol.*, 62(1): 106-14.

References

- Roger G., Worthington, P.C., (2005).** <http://www.aml-benzene.com/pages/aml-diagnosis.htm>.
- Ronald Hoffman, Edward Benz, Jr, Sanford Shattil, et al, (2005):** Hematology: Basic Principles and Practice, 4th edition. St. Louis. Mo.: Elsevier Churchill Livingstone.
- Rooney DE and Crepulkowski BH. (1992):** Human cytogenetics. In: Rooney, D.E. and Czepulkowski B.H (eds): A Practical Approach. Oxford University press, New York. 2nd edition.; p.140.
- Roumier C, Eclache V, Imbert M, et al. (2003):** M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Français d'Hématologie Cellulaire (GFHC) and the Groupe Français de Cytogénétique Hématologique (GFCH). Blood 101 (4): 1277-83.
- Rowe D, Cotterill SJ, Ross FM, et al (2000):** Cytogenetically cryptic AML1-ETO and CBFB-MYH11 gene rearrangements: incidence in 412 cases of acute myeloid leukaemia. Br J Haematol, 111: 1051-1056.
- Rowe D, Strain L, Lowe C, Jones G. (2007):** A case of acute myeloid leukemia with inv(16)(p13q22) reveals a novel MYH11 breakpoint and a new CBF beta-MYH11 transcript variant. Haematologica ; 92:1433-4.
- Rowe D., Cotterill S.J., Ross F.M. and Bunyan D.G.(2000):** Cytogenetical cryptic AML1/ETO and CBFB/MYH11 gene rearrangement: Incidence in 421 cases of acute myeloid leukemia. Br.J.Hematol., 111(4): 1051-1056.
- Rowley J.D.(2000),** Cytogenetic analysis in leukemia and lymphoma: An introduction. *Semin Hematol* 37 (2000), pp. 315–319.
- Rowley JD. (1999).** The role of chromosome translocations in leukemogenesis. *Semin Hematol.* Oct: 36(4 Suppl 7): 59-72. .

- Rubnitz JE., Raimondi SC., Halbert AR., et al., (2002):** Characteristics and outcome of t (8; 21)-positive childhood acute myeloid leukemia: a single institution's experience. *Leukemia* 16 (10): 2072-7.
- Sakuma T, Hayashi Y, Kanomata N, Murayama T, Matsui T, Kajimoto K, Hanioka K, Chihara K, Maeda S. (2006).** Histological and cytogenetic characterization of bone marrow in relation to prognosis and diagnosis of myelodysplastic syndromes. *Pathol Int.* Apr; 56(4): 191-9.
- Sambrook, Joseph; and David W, Russell (2001):** Molecular Cloning :A Laboratory Manual. 3rd ed .Cold Spring Harbor,N.Y.: Cold Spring Harbor Laboratory Press.
- Schmidt W., Jenderny J., Hecher K., Hackeloer B. (2000):** Detection of aneuploidy in chromosomes X, Y, 13, 18, and 21 by QF-PCR in 662 selected pregnancies at risk. *Molecular Human Reproduction*, 6(9): 855-860.
- Schnittger S, Bacher U, Haferlach C, Kern W, Haferlach T. (2007):** Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients. *Leukemia*; 21:725-31.
- Schnittger S., Weisser M., Schoch C., Hiddemann W., Haferlach T. and Kern W. (2003),** New score predicting for prognosis in PML-RARA+, AML1-ETO+ or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts, *Blood* 102 (2003), pp. 2746-2755.
- Schoch C., Schnittger S., Klaus M., et al., (2003):** AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. *Blood* 102 (7): 2395-402.

References

- Schrok E, Du Manoir S, Veldman T, et al., (1996):** Multicolor spectral karyotyping of human chromosomes. *Science*. 1996; 273(5274): 494-7.
- Shattuck-Brandt RL and Brandt. (1999):** Molecular genetics and hematology, Wintrobe's Clinical Hematology, 10th edition by Lee, G.R., Forester J., Lukens J., Parskebas F., Greer J.P., Rodgers G.M. (eds) Mass Publishing co; p 124-42.
- Sherr CJ (2004):** Principles of tumor suppression. *Cell*. 116(2): 235-46.
- Shih LY., Kuo MC., Liang DC., et al., (2003):** Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) genes in acute promyelocytic leukemia. *Cancer* 98 (6): 1206-16.
- Shrihari S.K., Annette B, Carol D, et al (2004):** Comprehensive Analysis of CBFβ-MYH11 fusion transcripts in acute myeloid leukemia by RT-PCR analysis. *J Mol Diagn*, 6: 22-27.
- Sievers EL, Larson RA, Stadtmauer EA, et al (2001).** "Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse". *J. Clin. Oncol.* 19 (13): 3244-54.
- Slack JL, Arthur DC, Lawrence D, Mrozek K, Mayer RJ, et al., (1997).** Secondary cytogenetic changes in acute promyelocytic leukemia—prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene; a Cancer and Leukemia Group B study. *J Clin Oncol.* May; 15(5):1786-95. 1997.
- Smith S, Hwang JY, Banerjee S, Majeed A, Gupta A, Myung K (2004).** Mutator genes for suppression of gross chromosomal rearrangements identified by a genome-wide screening in *Saccharomyces Cerevisiae*. *Proc Natl Acad Sci U S A*. 2004; 101(24): 9039-44.
- Smith SM, Le Beau MM, Huo D, et al. (2003):** Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. *Blood* 102 (1): 43-52.

References

- Soignet SL, Frankel SR, Douer D, et al. (2001).** "United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia". *J. Clin. Oncol.* 19 (18): 3852-60.
- Speicher MR, Gwyn Ballard S, Ward DC. (1996):** Karyotyping human chromosomes by combinatorial multi-fluor FISH. *Nat Genet.* 1996; 12(4): 368-75.
- Steensma DP, List AF. (2005).** Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity. *Mayo Clin Proc.*;80(5):681-98
- Steensma DP, Tefferi A (2003):** The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. *Leuk Res* 27 (2): 95-120.
- Sternberg N. (1990):** Bacteriophage P1 cloning system for the isolation, amplification, and recovery of DNA fragments as large as 100 kilobase pairs. *Proc Natl Acad Sci USA.* ; 87(1): 103-7.
- Stevens R.F., Hann I.M., Wheatley K. & Gray R.G. (1998):** Marked improvement in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council's 10th AML trial. *British Journal of Hematology* 101, 130-140.
- Stolfus P.K., Rust D. and Ried T. (2001),** Molecular cytogenetics and gene analysis: Implications for oncology nurses. *Clin J Oncol Nurs* 5 , pp. 201-206.
- Stone R.M. (2001):** Postremission therapy in adults with acute myeloid leukemia. *Semin Hematol* 38, pp. 17-23.
- Strehl S, Ambros PF. (1993):** Fluorescence in situ hybridization combined with immunohistochemistry for highly sensitive detection of chromosome 1 aberrations in neuroblastoma. *Cytogenet Cell Genet.* 1993; 63(1): 24-8.

References

- Strehl S., Kunig M., Mann G., et al (2001):** Multiplex reverse transcriptase-polymerase chain reaction screening in childhood acute myeloblastic leukemia. *Blood*, 97: 805-808.
- Sung J, Turner J, McCarthy S, Enkemann S, Li CG, Yan P, Huang T, Yeatman TJ. (2005).** Oncogene regulation of tumor suppressor genes in tumorigenesis. *Carcinogenesis*. 26(2): 487-94.
- Swerdlow SH, Campo E, Harris NL, et al (2008):** WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press.
- Tallman MS, (2004).** Relevance of pathologic classifications and diagnosis of acute myeloid leukemia to clinical trials and clinical practice. *Cancer Treat Res*; 121: 45-67.
- Tallman MS, Andersen JW, Schiffer CA, et al (2002):** All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. *Blood* 100 (13): 4298-302.
- Tallman MS. (2006).** New agents for the treatment of acute myeloid leukemia. *Best Pract Res Clin Haematol.*; 19(2):311-20.
- Thandla S. and Aplan P.D. (1997),** Molecular biology of acute leukemia. *Semin Oncol* 24, pp. 45–56.
- Thompson MA. (2003).** Molecular genetics of acute leukemia. In: Wintrob's clinical hematology. Thompson MA. (ed.), p. 2046-2062.
- Tosi S, Harbott J, Haas OA, Douglas A, et al., (1996).** Classification of deletions and identification of cryptic translocations involving 7q by fluorescence in situ hybridization (FISH). *Leukemia*. 1996; 10(4): 644-9.
- Trewhitt K.G., (2001)** Bone marrow aspiration and biopsy: Collection and interpretation. *Oncol Nurs Forum* 28 , pp. 1409–1417.

References

- Trost D, Hildebrandt B, Beier M, Muller N, et al., (2006).** Molecular cytogenetic profiling of complex karyotypes in primary myelodysplastic syndromes and acute myeloid leukemia. *Cancer Genet Cytogenet.* Feb; 165(1): 51-63.
- Une T, Yokoyama Y, Ninomyia S, Shinozuka M, et al., (2006).** Assessment of molecular cytogenetic methods for the detection of chromosomal abnormalities. *Acta Med Okayama*, Oct; 60(5):279-87.
- Vaandrager JW, Schuurin E, Zwikstra E, et al., (1996):** Direct visualization of dispersed 11q13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization. *Blood*; 88(4): 1177-82.
- Van Dongen J.J.M., Macintyre E.A., Gabert J.A. et al. (1999),** Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. *Leukemia* 13 (1999), pp. 1901-1928.
- Van Gijlswijk RP, Talman EG, Janssen PJ, et al., (2001):** Universal Linkage System: versatile nucleic acid labeling technique. *Expert Rev Mol Diagn.* 2001; 1(1): 81-91.
- Van Hummelen P, Lowe XR, Wyrobek AJ. (1996):** Simultaneous detection of structural and numerical chromosome abnormalities in sperm of healthy men by multicolor fluorescence in situ hybridization. *Hum Genet.* 1996; 98(5): 608-15.
- Van Limbergen H, Poppe B, Janssens A., et al., (2002):** Molecular cytogenetic analysis of 10; 11 rearrangements in acute myeloid leukemia. *Leukemia* 16 (3): 344-51.
- Vardiman JW., Harris NL., Brunning RD. (2002):** The World Health Organization (WHO) classification of the myeloid neoplasms". *Blood* 100 (7): 2292-302. Doi: 10.1182/blood 4-1199.

References

- Verlinsky Y, Cieslak J, Freidline M, et al., (1996):** Polar body diagnosis of common aneuploidies by FISH. *J Assist Reprod Genet.* 1996; 13(2): 157-62.
- Verma RS, Da Costa M, Gogineni SK, Palermo G. (1993):** New translocation involving homologous chromosome 3 in acute myelogenous leukemia (M2). *Am J Hematol.* 1993; 42(4): 398-9.
- Vet J.A., Majithia A.R., Marras S.A. and Tyagi S. (1999):** Multiplex detection of four pathogenic retroviruses using molecular beacons. *Proc. Natl. Acad. Sci.*, 96(11): 6394-99.
- Wang L, Lin D, Zhang X, et al. (2005):** Analysis of FLT3 internal tandem duplication and D835 mutations in Chinese acute leukemia patients. *Leuk Res* 29 (12): 1393-8.
- Weier HU, Greulich-Bode KM, Ito Y, et al, (2002):** FISH in cancer diagnosis and prognostication: from cause to course of disease. *Expert Rev Mol Diagn.* 2002; 2(2): 109-19.
- Wells RJ., Arthur DC., Srivastava A., et al., (2002):** Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children's Cancer Group Study 213. *Leukemia* 16 (4): 601-7.
- Wessman M, Popp S, Ruutu T, et al, (1993):** Detection of residual host cells after bone marrow transplantation using non-isotopic in situ hybridization and karyotype analysis. *Bone Marrow Transplant.* 1993;11(4):279-84
- Whitlock JA and Gaynon PS (1999):** Quoted from Wintrobe's Clinical Hematology. 10th ed. Williams and Wikins Company, Philadelphia, p2241-2271.
- Whitter PA, Campbell AJ, Souther E and Murray N. (1988):** Enhanced recovery and restriction mapping of DNA fragments cloned in a new lambda vector. *Nucl Acid Res*, 16: 6725.

References

- Wickremasinghe RG and Hoffbrand AV, (2000).** Molecular hematology. Provan D. and Gribben J. (eds.), Black well science, Oxford; Ch.3, p: 25.
- Wikipedia, the free encyclopedia, Acute myeloid leukemia, 12 December 2006.**
- Wittwer C.T., Herrmann M.G., Gundry C.N. and Elenitoba-johnson K.S. (2001):** Real time multiplex PCR assays. *Methods*, 25(4):430-42.
- Woo HY, Kim DW, Park H, et al, (2005):** Molecular cytogenetic analysis of gene rearrangements in childhood acute lymphoblastic leukemia. *J Korean Med Sci.* Feb; 20(1):36-41.
- Wullich B, Morgan R, Berger C, et al, (1991):** Nonradioactive in situ hybridization. A rapid approach for the identification of marker chromosomes: study of a case of acute leukemia with a Yq specific DNA probe. *Cancer Genet Cytogenet.* 1991; 52(2): 165-72.
- Yamauchi K, Yasuda M (2002):** Comparison in treatments of nonleukemic granulocytic sarcoma: report of two cases and a review of 72 cases in the literature. *Cancer* 94 (6): 1739-46.
- Yanada M, Matsuo K, Suzuki T, et al (2005):** Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. *Leukemia* 19 (8): 1345-9.
- Yoshinaga S., Mabuchi K., Sigurdson A., Doody M., Ron E. (2004):** "Cancer risks among radiologists and radiologic technologists: review of epidemiologic studies". *Radiology* 233 (2): 313-21.
- Zaccaria A, Valenti A, Toschi M, et al. (2002):** Cryptic translocation of PML/RARA on 17q. A rare event in acute promyelocytic leukemia. *Cancer Genet Cytogenet* 138 (2): 169-73.
- Zahed L, Murer-Orlando M, Vekemans M. (1992):** In situ hybridization studies for the detection of common aneuploidies in CVS. *Prenat Diagn.* 1992; 12(6): 483-93.

APPENDIX

Table(I): Symptoms of the study group

No.	FAB Diagnosis	Age	Sex	Symptoms of the study group						
				Fatigue	Pallor	Purpura	Abdominal swelling	Boneaches	Epistaxis	Neck swelling
1.	M2	34	Male	+	+	+	-	+	+	-
2.	M1	36	Male	-	-	-	-	-	-	-
3.	M2	40	Male	+	+	+	+	+	+	-
4.	M4Eo	23	Male	-	-	-	-	-	-	+
5.	M5a	42	Male	+	+	+	-	+	-	-
6.	M2	58	Male	+	+	+	+	+	-	+
7.	M4	60	Male	+	+	+	+	+	+	+
8.	M3	30	Male	+	+	+	-	+	+	+
9.	M3	47	Male	+	+	+	-	+	+	-
10.	M2	51	Female	+	+	+	+	+	+	-
11.	M4	65	Male	+	+	+	+	+	+	+
12.	M4	59	Male	+	+	+	+	+	+	+
13.	M2	45	Female	+	+	-	-	+	+	+
14.	M2	47	Male	+	+	-	-	+	-	+
15.	M4Eo	46	Male	-	-	-	-	+	-	-
16.	M4	59	Female	+	+	+	+	+	+	-
17.	M3	52	Male	+	+	+	-	+	+	+
18.	M3	63	Female	+	+	+	+	+	+	-
19.	M2	31	Male	-	-	-	-	-	+	+
20.	M2	54	Female	+	+	+	+	+	-	-
21.	M4	57	Male	+	+	+	-	+	+	+
22.	M1	55	Female	+	+	-	-	+	-	+
23.	M2	45	Male	+	+	+	+	+	-	-
24.	M4	50	Male	+	+	+	-	+	+	+
25.	M2	60	Female	+	+	+	+	+	+	+
26.	M2	41	Female	+	+	-	-	+	-	-
27.	M3	39	Female	+	+	-	-	+	-	-
28.	M3	63	Male	+	+	+	+	+	+	+
29.	M4	54	Female	+	+	+	+	+	-	+
30.	M5a	66	Male	+	+	+	+	+	+	+
31.	M3	41	Female	+	+	-	-	+	-	+
32.	M1	44	Female	+	+	-	-	+	-	-
33.	M2	55	Male	+	+	+	+	+	+	+
34.	M3	64	Male	+	+	-	-	+	-	-
35.	M2	52	Female	+	+	-	-	+	-	-
36.	M3	61	Female	+	+	-	-	+	-	-
37.	M1	45	Female	+	+	-	-	+	-	-
38.	M2	55	Male	+	+	-	-	+	-	-
39.	M4	59	Male	+	+	-	-	+	-	-
40.	M2	44	Male	+	+	-	-	+	-	-

Table (II): Signs of the study group

No.	FAB Diagnosis	Age	Sex	Signs of the study group			
				Fever	Lymphadenopathy	Hepatomegally	Splenomegally
1.	M2	34	Male	-	-	-	-
2.	M1	36	Male	-	-	-	-
3.	M2	40	Male	+	+	+	+
4.	M4Eo	23	Male	-	-	+	+
5.	M5a	42	Male	+	-	-	-
6.	M2	58	Male	+	+	+	+
7.	M4	60	Male	+	+	+	+
8.	M3	30	Male	+	-	+	+
9.	M3	47	Male	+	-	-	-
10.	M2	51	Female	+	+	+	+
11.	M4	65	Male	+	+	+	+
12.	M4	59	Male	+	+	+	+
13.	M2	45	Female	-	-	-	-
14.	M2	47	Male	+	-	-	-
15.	M4Eo	46	Male	-	-	-	-
16.	M4	59	Female	+	+	+	+
17.	M3	52	Male	+	-	-	-
18.	M3	63	Female	+	+	+	+
19.	M2	31	Male	-	-	-	-
20.	M2	54	Female	+	+	+	+
21.	M4	57	Male	+	-	-	-
22.	M1	55	Female	+	-	-	-
23.	M2	45	Male	-	+	+	+
24.	M4	50	Male	+	-	-	-
25.	M2	60	Female	+	+	+	+
26.	M2	41	Female	+	-	-	-
27.	M3	39	Female	+	-	-	-
28.	M3	63	Male	+	+	+	+
29.	M4	54	Female	+	+	+	+
30.	M5a	66	Male	+	+	+	+
31.	M3	41	Female	-	-	-	-
32.	M1	44	Female	+	-	+	+
33.	M2	55	Male	+	+	+	+
34.	M3	64	Male	+	-	-	-
35.	M2	52	Female	+	-	-	-
36.	M3	61	Female	+	-	-	-
37.	M1	45	Female	+	-	-	-
38.	M2	55	Male	-	-	-	-
39.	M4	59	Male	-	-	+	+
40.	M2	44	Male	-	-	-	-

Table (III): Laboratory and Survival data of the patients:

No.	Hb	TLC	Plt	PB BL %	BM BL %	PCR	FISH	Fate	A/D	OS	DFI	EFS
1.	3.5	73	28	73	100	t(8;21)	AML1/ETO	C.R.	Alive	23	-	-
2.	7.2	185	26	90	95	---	---	Relapse	Died	12	3	8
3.	2.7	38.7	15	85	100	t(8;21)	AML1/ETO	C.R.	Alive	23	-	-
4.	5.2	46	12	98	100	inv(16)	CBFB/MYH11	C.R.	Alive	23	-	-
5.	7.1	160	30	82	95	---	---	No Rem	Died	1	-	1
6.	9.5	10.3	55	85	95	---	---	Relapse	Died	8	2	6
7.	2.7	3.5	30	32	76	---	---	No Rem	Died	0.5	-	0.5
8.	8.1	52	85	40	78	t(15;17)	PML/RARA	C.R.	Alive	22	-	-
9.	5.9	27	78	30	75	---	---	Relapse	Died	15	3	7
10.	5.2	179	30	89	100	---	---	No Rem	Died	3	-	3
11.	4.2	50.3	61	32	56	---	---	No Rem	Died	1	-	1
12.	7.8	88	36	41	88	---	---	Relapse	Died	14	4	7
13.	9.4	7.8	5.5	46	72	t(8;21)	AML1/ETO	Relapse	Died	13	6	9
14.	6.9	23	32	38	45	---	---	Relapse	Died	12	3	7
15.	6.5	44	13	53	100	inv(16)	CBFB/MYH11	C.R.	Alive	21	-	-
16.	3.7	29	38	42	80	---	---	No Rem	Died	2	-	2
17.	8.2	47.5	71	28	58	t(15;17)	PML/RARA	Relapse	Died	12	5	8
18.	6.7	187	54	89	94	---	---	Relapse	Died	12	3	7
19.	7.1	3.3	90	80	91	t(8;21)	AML1/ETO	C.R.	Alive	19	-	-
20.	8.2	150	19	91	100	---	---	Relapse	Died	14	4	7
21.	4.6	133	53	74	97	---	---	No Rem	Died	1.5	-	1.5
22.	8.7	38	22	43	64	---	---	Relapse	Died	12	2	8
23.	9.1	31	28	32	54	t(8;21)	AML1/ETO	C.R.	Alive	19	-	-
24.	9.2	59	34	49	86	---	---	Relapse	Died	14	2	9
25.	6.2	44	19	44	65	---	---	No Rem	Died	0.5	-	0.5
26.	7.1	42	39	31	53	---	---	Del.Rem	Alive	18	-	-
27.	6.1	89	33	90	100	t(15;17)	PML/RARA	C.R.	Alive	18	-	-
28.	3.9	87	77	90	100	---	---	No Rem	Died	1.5	-	1.5
29.	8.2	49	58	47	87	---	---	Relapse	Died	15	3	7
30.	6.6	10	8.5	54	70	---	---	No Rem	Died	2	-	2
31.	5.8	43	59	60	96	t(15;17)	PML/RARA	C.R.	Alive	17	-	-
32.	4.9	22	19	37	55	---	---	Del.Rem	Alive	17	-	-
33.	7.8	49	90	70	90	---	---	Relapse	Died	13	3	6
34.	5.1	5.2	20	70	90	---	---	No Rem	Died	1	-	1
35.	6.8	12	48	40	70	---	---	Relapse	Died	15	4	8
36.	7.3	60.5	67	88	100	---	---	No Rem	Died	1	-	1
37.	5	6.8	45	43	65	---	---	Relapse	Died	16	5	9
38.	2.9	7.8	28	22	48	---	---	No Rem	Died	1.5	-	1.5
39.	4.1	3.8	33	40	70	---	---	Relapse	Died	2	-	2
40.	4.8	3.5	11	32	82	---	---	Relapse	Alive	16	-	-